Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Reposition Drugs for Eli Lilly

NEW YORK (GenomeWeb News) – Gene Logic today said it will try to discover new development paths for drug candidates discontinued in clinical trials by Eli Lilly.
 
The candidates were discontinued for reasons other than safety, Gene Logic said.
 
Under the deal, Gene Logic has the option to receive an exclusive license to any drug candidate Eli Lilly decides not to purse. Eli Lilly would receive success-based milestone and royalty payments on those candidates.
 
The milestone payments and royalties under the agreement are similar to those in development-stage in-licensing deals, Gene Logic said. The payments are discounted because Eli Lilly originated the compound.
 
Gene Logic has similar agreements with Pfizer, Roche, and Organon.
 
Additional details were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.